Form 4: Incyte Executive Awarded Performance Shares Tied to TSR

Incyte Corp's EVP, Head of Incyte International, Lee Heeson, was granted 6,577 performance shares on July 15, 2025, which can yield up to 200% of common stock based on the company's relative total shareholder return over a three-year period.

Summary

• Lee Heeson, Executive Vice President and Head of Incyte International, received a grant of 6,577 performance shares.
• The grant date for these performance shares was July 15, 2025.
• Each performance share represents the right to receive up to 200% of one share of Incyte common stock.
• The actual number of shares earned will be determined by Incyte's relative total shareholder return (TSR) compared to a fixed peer group over a three-year performance period, which began on January 1, 2025.
• The earned shares are scheduled to vest on July 15, 2028, contingent upon Mr. Heeson's continued service with Incyte.

Sentiment

Score: 7

Explanation: The grant of performance shares to a key executive is a positive sign of long-term incentive alignment and commitment, though it is a routine compensation event rather than a major strategic announcement.

Positives

• Executive compensation is directly aligned with shareholder interests through performance-based equity awards.
• The award incentivizes long-term value creation and strategic growth by linking payout to Incyte's total shareholder return relative to its peers.
• The structure encourages the executive to remain with the company until the vesting date, promoting retention.

Negatives

• The value of the award to the executive is not guaranteed and is entirely dependent on Incyte's future stock performance relative to its peer group.
• There is no immediate cash benefit to the executive from this grant.

Risks

• The actual number of common shares ultimately received by the executive is uncertain and depends on Incyte's total shareholder return performance against a predefined peer group over the three-year period.
• The executive must maintain continued employment with Incyte until the vesting date of July 15, 2028, to receive any earned shares.

Future Outlook

The performance share award is designed to incentivize Incyte's executive management to drive strong total shareholder return over a three-year period ending July 15, 2028, thereby aligning their interests with long-term shareholder value creation.

Industry Context

Performance-based equity awards, particularly those tied to relative Total Shareholder Return (TSR), are a common and widely accepted practice in the biotechnology and pharmaceutical industries. This compensation structure aims to align executive incentives with long-term shareholder value and competitive performance within a defined peer group, reflecting a broader industry trend towards pay-for-performance models.

Comparison to Industry Standards

• The use of performance shares tied to relative Total Shareholder Return (TSR) over a multi-year period is a standard practice for executive compensation in the pharmaceutical and biotechnology sectors, comparable to structures seen at companies like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals.
• The 'up to 200%' payout for performance shares is a common multiplier, indicating a strong incentive for superior performance against a peer group.
• The three-year performance and vesting period is typical for long-term incentive plans in the industry, balancing short-term results with sustained growth and executive retention.

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is directly tied to Total Shareholder Return, aligning management's interests with shareholder value creation.
• Employees: No direct impact on general employees, but it highlights the company's executive compensation structure for key personnel.

Next Steps

• Incyte's performance relative to its peer group will be monitored over the three-year period ending January 1, 2028, to determine the final payout of the performance shares.
• The executive's continued service with Incyte until July 15, 2028, is required for the vesting of the earned shares.

Key Dates

Recommendation

Keywords

Incyte Corp, INCY, SEC Form 4, Performance Shares, Executive Compensation, Equity Award, Total Shareholder Return, TSR, Stock Grant, Insider Transaction